Recruiting

AI-guided treatment plan to prevent liver cancer from returning after surgery

Plain-English translation of NCT07282184 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new approach to treating early-stage liver cancer by using artificial intelligence to predict which patients are at highest risk of their cancer returning after surgery. For patients identified as high-risk, the study tests whether receiving chemotherapy combined with immunotherapy before surgery, followed by standard surgery and additional medication after surgery, works better than surgery alone at preventing cancer recurrence. The goal is to see if this personalized, AI-guided treatment plan can significantly reduce the chance of the cancer coming back within 2 years.

Liver cancer often comes back after surgery, even in early stages, and doctors currently have limited ways to predict who is at highest risk or how to best prevent recurrence. This study exists to see whether artificial intelligence can identify high-risk patients earlier and whether adding medication before and after surgery can improve outcomes for those patients.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with early-stage liver cancer (BCLC stage 0-A) confirmed by imaging or biopsy
you are scheduled to have liver surgery with the goal of removing the cancer completely
artificial intelligence analysis of your medical images and data predicts you are at high risk for cancer recurrence
you have good liver function (Child-Pugh Class A) and good overall health status
you have a recent MRI scan available from within the past month and are willing to commit to 2 years of follow-up visits

You likely don't qualify if…

you have a different type of liver cancer or cancer besides hepatocellular carcinoma
you have been diagnosed with another active cancer in the past 5 years
you have a severe allergy or intolerance to any of the medications being tested (chemotherapy, immunotherapy, or lenvatinib)
you have uncontrolled heart disease, severe kidney problems, or severely uncontrolled high blood pressure
you are unable or unwilling to attend regular follow-up visits and scans for at least 2 years

What participation looks like

If you qualify for the study, artificial intelligence will analyze your medical images to determine your risk level. If you are identified as high-risk, you will either receive medication (chemotherapy and immunotherapy) before surgery followed by liver surgery and additional medication afterward, or proceed directly to surgery alone (the study compares both approaches). Either way, you will have regular check-ups and imaging scans every few months for 2 years to monitor your health and watch for any signs of cancer recurrence. The study involves visits to the hospital for treatment and follow-up appointments, with careful monitoring to ensure the medications are safe and working.

AI-generated summary from trial data · Jul 6, 2026 · Not medical advice

AI-guided treatment plan to prevent liver cancer from returning after surgery

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)